Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.50 |
| ▸ | ATP4A | P20648 | 15/20 | 0.46 |
| ▸ | ATP4B | P51164 | 15/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4744464 | 0.82 | ATP4A (0.45) | CETPATP4AATP4BNPC1TP53 | |
| SCHEMBL8717019 | 0.81 | NPC1 (0.52) | CETPNPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL1849761 | 0.81 | PPARG (0.66) | — | |
| SCHEMBL12521715 | 0.81 | PPARG (0.66) | — | |
| SCHEMBL1849759 | 0.81 | PPARG (0.66) | — | |
| SCHEMBL1989519 | 0.80 | NPC1 (0.40) | CETPNPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL1849764 | 0.80 | PPARG (0.52) | CETP | |
| SCHEMBL31201856 | 0.80 | CETP (0.49) | CETPNPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL9803918 | 0.79 | ATP4A (0.51) | ATP4AATP4BSMN1; SMN2 | |
| SCHEMBL4744468 | 0.74 | PPARG (0.63) | ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263587-B2 | Benzoxazepine compounds, their preparation and use | PIRAMAL HEALTHCARE LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| EP-2077846-B1 | BENZOXAZEPINE COMPOUNDS, THEIR PREPARATION AND USE | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-10-12 | — | — | EP | disclosed |
| US-20110152247-A1 | BENZOXAZEPINE COMPOUNDS, THEIR PREPARATION AND USE | Piramal Enterprises Limited (IN) | 2011-06-23 | — | — | US | disclosed |
| EP-2077846-A2 | BENZOXAZEPINE COMPOUNDS, THEIR PREPARATION AND USE | Piramal Life Sciences Limited (IN) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008053446-A2 | BENZOXAZEPINE COMPOUNDS, THEIR PREPARATION AND USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-05-08 | — | — | WO | disclosed |
| US-6686475-B2 | THIAZOLIDINEDIONE DERIVATIVES HAVING HYPOGLYCAEMIC AND HYPOLIPIDAEMIC ACTIVITIES | BEECHAM GROUP P.L.C. (GB) | 2004-02-03 | — | — | US | disclosed |
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | BEECHAM GROUP P.L.C. | 2003-08-07 | — | — | US | disclosed |
| US-20020049240-A1 | NOVEL COMPOUNDS | BEECHAM GROUP P.1.C. | 2002-04-25 | — | — | US | disclosed |
| US-6288095-B1 | ADMINISTERING 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE TO MAMMALS AS AN ANTIDIABETIC | BEECHAM GROUP P.L.C. (GB) | 2001-09-11 | — | — | US | disclosed |
| US-5646169-A | ADMINISTERING SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES TO HUMANS OR OTHER MAMMALS | BEECHAM GROUP P.L.C. (GB) | 1997-07-08 | — | — | US | disclosed |
| US-5521201-A | SUBSTITUTED-THIAZOLIDINEDIONE DERIVATIVES | BEECHAM GROUP P.L.C. | 1996-05-28 | — | — | US | disclosed |
| US-5260445-A | Hypoglycemic | BEECHAM GROUP P.L.C. (GB) | 1993-11-09 | — | — | US | disclosed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | disclosed |
| US-5194443-A | Thiazolinediones, Hypoglycemic Agents, Antilipemic Agents | BEECHAM GROUP P.L.C. (GB) | 1993-03-16 | — | — | US | disclosed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152247-A1 | BENZOXAZEPINE COMPOUNDS, THEIR PREPARATION AND USE | GPR119, INSR, SLC5A1 | CETP 2723/4885ATP4A 734/4885ATP4B 587/4885 |
| US-20030149054-A1 | Administering thiazolidinedione derivatives for therapy and prophylaxis of cardiovascular diseases or eating disorders in a human or non- human mammal | TYK2, FABP3, FABP4 | CETP 298/4885ATP4A 1793/4885ATP4B 3152/4885 |
| US-20020049240-A1 | NOVEL COMPOUNDS | GRK1, GRK3, GRK7 | CETP 347/4885ATP4A 2743/4885ATP4B 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.